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Summary Individuals with a deficiency in the enzyme dihydropyrimidine dehydrogenase (DPD) may experience severe life-threatening
toxicity when treated with 5-fluorouracil (5-FU). As routine measurement of enzyme activity is not practical in many clinical centres, we have
investigated the use of DNA mutation analysis to identify cancer patients with low enzyme levels. We have identified two new mutations at
codons 534 and 543 in the DPD cDNA of a patient with low enzyme activity and screened the DNA from 75 colorectal cancer patients for
these mutations and the previously reported splice site mutation (Vreken et al, 1996; Wei et al, 1996). In all cases, DPD enzyme activity was
also measured. The splice site mutation was detected in a patient (1 out of 72) with low enzyme activity whereas mutations at codons 534
(2 out of 75) and 543 (11 out of 23) were not associated with low enzyme activity. These studies highlight the need to combine DPD genotype
and phenotype analysis to identify mutations that result in reduced enzyme activity.
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5-Fluorouracil (5-FU) is widely used in the treatment ofadvanced
solid tumours, including colorectal, breast and head/neck tumours.
5-FU is also frequently used in adjuvant chemotherapy for
colorectal and breast cancers, in which its mild toxicity profile of
mucositis and diarrhoea is well tolerated by patients who are at
risk for tumour recurrence buthave no current evidence ofdisease.
5-FU is a pyrimidine analogue and greater than 80% of a dose is
degraded in athree-step pathway, initially catalysedby the enzyme
dihydropyrimidine dehydrogenase (DPD; E.C. 1.3.1.2., Heggie et
al, 1987). Deficiency in DPD enzyme activity is associated with a
considerable delay in clearance of 5-FU from the plasma (Diasio
et al, 1988; Fleming et al, 1992), leading to severe, life-threatening
diarrhoea, neutropenia and in some cases neurotoxicity, incurring
prolonged hospitalization (Milano and Etienne, 1996). High
concentrations ofplasma and urine 5-FU, uracil and thymine may
be detected along with low mononuclear cell DPD activity in these
patients. The toxicity is thought to result from higher levels of
5-FU entering the anabolic pathway, resulting in an increased
production of cytotoxic nucleotides. Although thymidine rescue
has been attempted in one case (Takimoto et al, 1996), the majority
of cases have been managed with supportive care after the cessa-
tion of 5-FU-based therapy. DPD activity is found in most human
tissues, with the highest levels in the liver and lymphocytes.
Population studies of peripheral blood mononuclear cell
(PBMNC) DPD have shown that enzyme activity is variable with
a seven- to 10-fold range observed (Lu et al, 1993; Etienne et al,
1994; McMurrough and McLeod, 1996). These studies suggest
that although total deficiency is rare in adults, as many as 3% of
the population may have low enzyme levels and thus be at
Received 1 April 1997
Revised 3July 1997
Accepted 9July 1997
Correspondence to: H McLeod
increased risk of severe toxicity if treated with 5-FU. Such indi-
viduals wouldbenefitfrom identification before the administration
of 5-FU-based therapy, particularly in the context of adjuvant
treatment. One mutation in the DPYD gene has been reported to
date in patients exhibiting severe toxicity after 5-FU treatment: a
mutation at a splice donor site leading to the skipping of a 165-bp
exon (Vreken et al, 1996; Wei et al, 1996). The splice site mutation
may be present in 1% of Finnish individuals but is much rarer in
British, Japanese, Afro-American and Dutch individuals (Vreken
et al, 1996; Wei et al, 1996), although in these studies the DPD
activity ofthe individuals tested was not measured.
In this study, we provide the first phenotype and specific geno-
type analysis of DPD in a colorectal cancer population. The
frequency of the splice site mutation and its association with low
DPD enzyme activity was studied. In addition, we describe two
mutations in the DPYD gene of a patient who experienced severe
5-FU-related toxicity and studied the frequency ofthese mutations
in colorectal cancer patients. Details of both the DPD genotype
and phenotype have provided valuable information regarding the
clinical application of polymerase chain reaction (PCR)-based
assays for prevention of5-FU-associated toxicity.
MATERIALS AND METHODS
Patient samples
The proband was a 65-year-old man who experienced severe
chemotherapy-induced toxicity after receiving 5 days of adjuvant
5-FU therapy after resection of a Duke's stage C carcinoma (Wei
et al, 1996). Samples were also obtained from 75 patients with
colorectal cancer who had received potentially curative resections
for colorectal cancer or were being treated for advanced disease at
Aberdeen Royal Infirmary. Twenty-six patients had Duke's stage
B, 40 Duke's stage C and nine Duke's stage D (aged 29-82 years).
The majority of patients were randomized in the ongoing
497498 SA Ridge etal
QUASAR trial, which involves the use of adjuvant 5-FU and
folinic acid-based chemotherapy. The remainder received a folinic
acid and bolus infusional 5-FU regimen for advanced metastatic
disease. These studies were approved by the local ethical
committee and informed consent was obtained from all patients.
Enzyme activity
DPD catalytic activity was measured in mononuclear cells from
20 ml of heparinized blood, using a previously described high-
performance liquid chromatography (HPLC)-based method for
the detection of ['4C]5-FU metabolites (McMurrough and
McLeod, 1996).
Identification of mutations
The identification ofthe G to A mutation at a splice donor site in the
DPYD gene has been previously described (Wei et al, 1996).
Mutations at codons 534 and 543 ofthe DPYD gene were identified
by amplifying a 465-bp fragment of DPD cDNA using primers QF
(5'-CACTCCTATTGATCTGGTGGAC-3') and QR (5'-CATTCCT-
ClTTTCTCCCATGC-3') (Yokota et al, 1994). The PCR fragments
were cloned into the pTAg vector (R&D Systems) and sequenced
with primers flanking the cloning site (5'-SEQ 5'-GCTATGAC-
CATGATTACGCCAA-3' and 3'SEQ 5'-TGTAAAACGACG-
GCCAGTGAA-3') according to the manufacturer's instructions.
Fluorescently labelled dideoxynucleotides were used and the prod-
ucts analysed by a ABI 373 DNA sequencer (Applied Biosystems).
Screening for mutations
Genomic DNA was extracted from whole blood using the Nucleon
II extraction method (Scotlab). The presence of a G to A mutation
at the splice donor site was detected using PCR to amplify a 258-
bp fragment from genomic DNA using primers DPDdelF2 (5'-
GAACCACCTCTGGCCCCACGTATG-3'; incorporates a Tail
site) and DPDdelR1 (5'-CAGCAAAGCAACTGGCAGATTC-3').
Reactions were carried out in 10 mM Tris-HCl pH 9.0, 50 mM
potassium chloride, 0.1% Triton X-100, 1.5 mm magnesium
chloride, 0.8 mM dNTP, 100 ng of each primer, 2.5 units of
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Figure 1 Detection of the splice site mutation in patient 1. DNA amplified
using primers delF2 and delR1 was digested with Tail. Heterozygous
mutations (+/-) were detected in the original proband (lane 3) and patient 1
(lane 4), as demonstrated by the presence of the 237-bp, 129-bp and 109-bp
fragments. Lane 2 contains DNA from a cell line that does not have the
mutation (+/+), with only the 129-bp and 109-bp bands present. Lane 1
contains uncut PCR (U) product. L, 100-bp DNA ladder (Pharmacia Biotech,
St Albans, UK)
Taq polymerase (Promega) and 100 ng of genomic DNA.
Amplification was carried out using 31 cycles of 94°C for 1 min,
58°C for 1 min and 72°C for 2 min. The presence of a mutation
was detected by digesting 10jl of each sample with TaiI
(Immunogen International) at 65°C for 4 h in 10 mm Tris-HCl pH
7.5, 10 mm magnesium chloride, 100 mm potassium chloride and
analysing the products on a 2.5% agarose gel. The presence ofthe
G to A mutation at the splice site destroys a Tail site (ACGT to
ACAT), resulting in the production of237-bp and 21-bp fragments
upon digestion. Ifthe wild-type sequence is present, 129-bp, 109-
bp and 21-bp fragments are produced. Serine to asparagine muta-
tions at codon 534 ofthe DPYD gene were detected by amplifying
a 160-bp fragment from genomic DNA using primers QF and
DPDR7 (5'-CAAGAGAGAAAGTlTlGGTG-3'). The remaining
reaction conditions were as above but with 2 mm magnesium chlo-
ride. The presence of a mutation was detected by digesting 10 ,l
of each sample with MseI (New England Biolabs) at 37°C for 4 h
in 10 mM Tris-HCl pH 7.9, 10 mm magnesium chloride, 50 mM
sodium chloride, 1 mM DTT, 100 ,ug ml-' bovine serum albumin
(BSA) and analysing on an 8% polyacrylamide gel. The presence
ofthe G to A mutation at codon 534 creates an MseI site (TTAA),
resulting in the production of 136-bp and 24-bp fragments upon
digestion. Isoleucine to valine mutations at codon 543 of the
DPYD gene were detected by amplifying a 77-bp fragment from
genomic DNA using primers QF and RsaRl (5'-CGCTAGCAA-
GACCAAAAGGATGTA-3'), with the other reaction conditions
as for codon 534. Ten microlitres ofeach sample was digested for
4 h at 37°C with RsaI (NBL Gene Sciences) in 10 mM Tris-HCl
pH 7.8, 10 mm magnesium chloride, 1 mm DTT. Because of the
incorporation ofa G at residue 22 in primer RsaRl (underlined), a
RsaI (GTAC) site is created if a A to G mutation is present at
codon 543. This results in theproduction ofa54-bpfragmentupon
digestion. The wild-type 77-bp fragment and the 54-bp mutation-
specific fragments were resolved by electrophoresis on a 10%
polyacrylamide gel. Controls with no DNA, known wild-type and
mutant DNAs were included in each analysis. The presence of
mutations was confirmed by sequencing PCR products directly
with the same primers used in the DNA amplification or by
cloning into the pTAg vector and sequencing using primers 5'SEQ
and 3'SEQ as described above.
RESULTS
Identification of DPYD mutations at codons 534 and 543
Amplification, cloning and sequencing the DPD cDNA fragments
from the proband demonstrated the presence of heterozygous
mutations that alterthe coding sequence atcodons 534 and 543. At
codon 534, a G to A transition (AGT to AAT) was detected and
would result in a serine to asparagine substitution. At codon 543,
an A to G transition (ATA to GTA) was detected and would result
in an isoleucine to valine substitution. The sequencing of cloned
PCR products indicated that the mutation at codon 543 was on the
same allele as the splice site mutation, whereas the codon 534
mutation was on the other allele (data not shown).
DPD enzyme activity
PBMNC DPD activity was detectable in all subjects analysed. DPD
activity was highly variable, with a 9.7-fold range of 42.6-412.3
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Figure 2 Detection of codon 534 mutations in patients 2 and 3. DNA
amplified using primers QF and DPDR7 was digested with Msel.
Heterozygous mutations (+/-) were detected in the original proband (lane 2)
and patients 2 (lane 3) and 3 (lane 4), as demonstrated by the presence of
160-bp and 136-bp fragments. DNA from a cell line that does not have the
mutation (+/+) is in lane 1. L, 1-Kb ladder (Life Technologies, Paisley, UK)
pmol min-' mg-' protein, a mean value of 210pmol min-m mg-1
protein and a %CV of 37.2%. Mononuclear cell DPD activity less
than 100 pmol min-' mg-' protein was observed in 7 of75 patients,
while 2 of 75 patients had less than 60 pmol min-1 mg-' protein
(lower limit of 95% distribution range). The proband with exces-
sive toxicity from 5-FU had a mononuclear cell DPD activity of34
pmol min-m mg-1 protein. This was 16% ofthe mean value found in
the 75 patients with colorectal cancer.
Frequency of DPYD mutations at the splice site and at
codon 534
The splice site mutation was detected in 1 of 72 patients
(Figure 1), with a DPD activity of 84.5 pmol min-' mg-' protein
(126 pmol min-' mg-' protein in an independent sample).
Mutations at codon 534 were detected in 2 of 75 patients (DPD
activity 213.6 and 412.3 pmol min-' mg-1, Figure 2). Further
details of these patients are shown in Table 1. The population
frequency of these mutant alleles in the colorectal patients was
0.7% (1 of 144 alleles) for the splice site mutation and 1.3% (2 of
150 alleles) for the codon 534 mutation.
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Figure 3 Detection of mutations at codon 543. DNA was amplified using
primers QF and RsaRl and digested with Rsal. Lanes 1, 2, 4 and 6 contain
DNA that does not have the mutation (+/+). Heterozygous (+/-) and
homozygous (-/-) mutations are shown in lanes 3 and 5 respectively. U,
uncut DNA; L, 1-Kb ladder
Mutations at DPYDcodon 543 are a common
polymorphism
We studied the frequency of mutations at codon 543 in 23 patients
with colorectal cancer (the first 20 collected and the three patients
with splice site or codon 534 mutations). We detected ten heterozy-
gous (DPD activity 44.1-335.4 pmol min-1 mg-' protein) and one
homozygous mutation (DPD activity 66.1 pmol min-1 mg-' protein)
(Figure 3), indicating a population allele frequency of26%.
DISCUSSION
Low DPD activity has important implications for the toxicity of
fluoropyrimidine therapies (Harris et al, 1991; Wei et al, 1996). It
would therefore be advantageous to identify such individuals
before the administration of therapy. As routine measurement of
enzyme activity is not technically feasible in many centres, we
have investigated the use ofDNA mutation analysis as an altema-
tive approach. We have identified two mutations in the DPD
cDNA of a patient with low enzyme activity, who experienced
severe toxicity after treatment with 5-FU. The frequency of these
mutations and their relationship to DPD enzyme activity were
Table 1 Details of patients with DPYDsplice site or codon 534 mutations
Patient Mutation in DPYD DPD activity Disease Treatment
(pmol min-' mg-'
protein)
1 Splice site +/- 84.5, 126 Duke's stage B Randomized to control
Codon 534 +/+ arm. Received no 5-FU
Codon 543 +/-
2 Splice site +/+ 412.3 Duke's stage D 5-FU and folinic acid
Codon 534 +/-
Codon 543 +/+
3 Splice site +/+ 213.6 Duke's stage B No treatment
Codon 534 +/-
Codon 543 +/+
+/+, wild type; +/-, heterozygous mutation.
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determined for the first time in a cohort of colorectal cancer
patients. In addition, the frequency of a previously reported splice
site mutation (Vreken et al, 1996; Wei et al, 1996) has also been
studied. Mutations at the splice site, codon 534 and codon 543
were detected in 0.7%, 1.3% and 26% of alleles respectively. The
high frequency of mutations at codon 543 and the large range
in DPD enzyme activity (44.1-335.4 pmol min-' mg-' protein)
suggest that this is a common polymorphism, which is not itself
associated with low enzyme activity. Heterozygous mutations at
codon 534 were also not associated with low enzyme activity
(213.6 and 412.3 pmol min-' mg-'), suggesting that this mutation
also does not significantly effect the function ofthe enzyme alone.
Low DPD activity was found in the patient with the splice site
mutation. The DPD activity level detected was 84.5 pmol min-'
mg-' protein in the initial sample and 126 pmol min-' mg-' protein
in a second sample. These levels are similar to those described in a
number of patients who have experienced severe 5-FU-related
toxicity (Hoyau et al, 1993; Lyss et al, 1993; Beuzeboc et al, 1996)
but are higher than previously reported in individuals with
heterozygous mutations at this splice donor site (Vreken et al,
1996; Wei et al, 1996). Although the reason for this is unclear, it is
possible that other mutations that effect DPD catalytic activity
may contribute to the lower activity observed in these individuals.
It is not possible to comment on the influence of the splice site
mutation on 5-FU toxicity in the individual from this study, as the
patient was randomized to receive observation alone. Current data
would suggest an increased risk of severe 5-FU-related toxicity
and that this should be considered in the event ofdisease relapse.
The mean DPD activity forthe colorectal cancerpatientpopula-
tion was 210 pmol min-' mg-' protein with a 9.7-fold range and a
%CV of37.2%. This is similar to that found in previous studies of
cancer patients (mean of 222 pmol min-' mg-' protein, 8.6-fold
range, %CV 37.8%) and healthy volunteers (mean of 189 pmol
min-' mg-' protein, 4.4-fold range, %CV 33.9%; Lu et al, 1993;
Etienne etal, 1994). Ithas been suggested that the cut-offvalue for
identification of suspected heterozygous DPD deficiency be set at
100 pmol min-' mg-' protein. In this study, seven patients fall
within this category, which is 9% ofthe total and muchhigherthan
the previously predicted 3-4% of the population (Lu et al, 1993;
Etienne et al 1994). However, if we consider those patients who
have activity below the lower limit of the 95% distribution range
(< 60 pmol min-1 mg-' protein), only two patients (2.7%) fall into
this category. This may be a more useful limit for predicting those
at risk fortoxicity. However, in the cohort studied here, the patient
with a splice site mutation had a DPD activity above this value and
this emphasizes the present difficulties associated with deter-
mining guidelines for identifying patients who may be at risk for
severe 5-FU toxicity. It is possible that the future identification of
more common inactivating mutations may clarify this.
The identification of two new mutations in this study and the
subsequent determination thatneitheralone are associated with low
enzyme activity highlight the importance of carrying out geno-
typing in the context of a population with known enzyme activity;
this also demonstrates that more than one mutation may be present
in an individual. Studies of heterologously expressed mutant
proteins willbe necessary todetermine the specific effects ofone or
more mutations on enzyme activity. Further investigations of the
seven individuals in this study with DPD enzyme activity below
100 pmol min-' mg-' protein may identify novel mutations that
improve the diagnostic use of PCR-based analysis for patients at
risk of5-FU toxicity.
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